NAVB stock is the biggest biotech stock gainer in Tuesday’s trading session after Navidea Biopharmaceuticals Inc (NYSE:NAVB) announced positive results of the first interim analysis of its ongoing phase 2B study on rheumatoid arthritis.
Solid BoostWhen it comes to big stock movements for pharmaceutical companies, then the release of positive updates with regards to clinical studies is usually one of the most popular triggers, and that is what happened with Navidea Biopharmaceuticals this morning. Earlier this morning, the company published a press release in which it stated that the data from an important clinical study ...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.